Treatment of rat brain tumors using sustained-release of camptothecin from poly(lactic-co-glycolic acid) microspheres in a thermoreversible hydrogel

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 9, 2010, Pages 1142-1147

  Ozeki, Tetsuya ^a   Hashizawa, Kosuke ^b   Kaneko, Daiki ^b   Imai, Yoshihiro ^b   Okada, Hiroaki ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Brain tumor; Camptothecin; Poly(lactic co glycolic acid) microsphere; Sustained release; Thermoreversible gelation polymer

Indexed keywords

CAMPTOTHECIN; MICROSPHERE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CYTOTOXICITY; GLIOBLASTOMA; GLIOMA CELL; HYDROGEL; MALE; NONHUMAN; RAT; ROOM TEMPERATURE; SURVIVAL TIME; SUSTAINED DRUG RELEASE; TUMOR GROWTH; TUMOR LOCALIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; GLIOMA; HYDROGEL; LACTIC ACID; MALE; MICROSPHERES; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE;

EID: 77956314483     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.1142     Document Type: Article

References (38)

1. Postomily R., Keles G. E., Berger M. S., Baillieres Clin. Neurol., 5, 345-369 (1996).
2. Cairncross J. G., MacDonald D. R., Ramsay D. A., Neurosurgery, 31, 78-82 (1992).
3. Hildebrand J., Dewitte O., Dietrich P. Y., de Tribolt N., Eur. Neurol., 38, 238-253 (1997).
4. Walker M. D., Green S. B., Byar D. P., Alexander E. Jr., Batzdof U., Brooks W. H., Hunt W. E., MacCarty C. S., Mahaley M. S. Jr., Owens G., Ransohoff J., Robertson J. T., Shapiro W. R., Smith K. R. Jr., Wilson C. B., Strike T. A., N. Engl. J. Med., 303, 1323-1329 (1980).
5. Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P., Cancer, 71, 2585-2597 (1993).
6. Stewart L. A., Lancet, 359, 1011-1018 (2002).
7. Bleehen N. M., Stenning S. P., Br. J. Cancer, 64, 769-774 (1991).
8. Garfield J., Dayan A. D., J. Neurosurg., 39, 315-322 (1973).
9. Shimura T., Teramoto A., Nakazawa H., Aihara K., Clin. Neuropathol., 15, 119-124 (1996).
10. Morikawa N., Mori T., Kawashima H., Takeyama M., Abe T., Kobayashi H., Biol. Pharm. Bull., 24, 436-438 (2001).
11. Wall M. E., Wani M. C., Cook C. E., Plamer K. H., J. Am. Chem. Soc., 88, 3888-3890 (1966).
12. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F., J. Biol. Chem., 260, 14873-14875 (1985).
13. Muggia F. M., Creaven P. J., Hansen H. H., Cohen M. H., Selawry O. S., Cancer Chemother. Rep., 56, 515-521 (1972).
14. Gottlieb J. A., Luce L. K., Cancer Chemother. Rep., 56, 103-105 (1972).
15. Moertel C. G., Schutt A. J., Reitemeier R. J., Hahn R. G., Cancer Chemother. Rep., 56, 95-101 (1972).
16. Creaven P. J., Allen L. M., Muggia F. M., Cancer Chemother. Rep., 56, 573-578 (1972).
17. Okuno S., Harada M., Yano T., Yano S., Kiuchi S., Tsuda N., Sakamura Y., Imai J., Kawaguchi T., Tsujihara K., Cancer Res., 60, 2988-2995 (2000).
18. Sawada S., Okajima S., Aiyama R., Nakata K., Furuta T., Yokokura T., Sugino E., Yamaguchi K., Miyasaka T., Chem. Pharm. Bull., 39, 1446-1450 (1991).
19. Alsner J., Svejstrup J. Q., Kjeldsen E., Sorensen B. S., Westergaard O., J. Biol. Chem., 267, 12408-12411 (1992).
20. Cersosimo R. J., Ann. Pharmacother., 32, 1334-1343 (1998).
21. Kobayashi K., Hino M., Fukuoka M., Takeuchi K., Furuse K., Yoneda S., Hasegawa K., Noda K., Kinoshita H., Kimura I., Taguchi T., Kanamaru R., Horikoshi N., Niitani H., Int. J. Clin. Oncol., 7, 177-186 (2002).
22. Sætern A. M., Flaten G. E., Brandl M., AAPS PharmSciTech., 5, article 40 (2004).
23. Sætern A. M., Skar M., Braaten Å., Brandl M., Int. J. Pharm., 288, 73-80 (2005).
24. Yokoyama M., Opanasopit P., Okano T., Kawano K., Maitani Y., J. Drug Target, 12, 373-384 (2004).
25. Opanasopit P., Yokoyama M., Watanabe M., Kawano K., Maitani Y., Okano T., Pharm. Res., 21, 2001-2008 (2004).
26. Barreiro-Iglesias R., Bromberg L., Temchenko M., Hatton T. A., Concheiro A., Alvarez-Lorenzo C., J. Controlled Release, 97, 537-549 (2004).
27. Conover C. D., Greenwald R. B., Pendri A., Shum K. L., Anti-Cancer Drug Des., 14, 499-506 (1999).
28. Fleming A. B., Haverstick K., Saltzman W. M., Bioconjug. Chem., 15, 1364-1375 (2004).
29. Tong W., Wang L., D'Souza M. J., Drug Dev. Ind. Pharm., 29, 745-756 (2003).
30. Storm P. B., Moriarity J. L., Tyler B., Burger P. C., Brem H., Weingart J., J. Neurooncol., 56, 209-217 (2002).
31. Okada H., Toguchi H., Crit. Rev. Ther. Drug Carrier Syst., 12, 1-99 (1995).
32. Okada H., Doken Y., Ogawa Y., Toguchi H., Pharm. Res., 11, 1143-1147 (1994).
33. Okada H., Adv. Drug Deliv. Rev., 28, 43-70 (1997).
34. Yoshioka H., Mikami M., Mori Y., Tsuchida E., J. Macromol. Sci., A31, 113-120 (1994).
35. Yoshioka H., Mikami M., Mori Y., Tsuchida E., J. Macromol. Sci., A31, 121-125 (1994).
36. Yoshioka H., Cushman J. A., Mori Y., Tsuchida E., Polym. Adv. Tech., 5, 122-127 (1994).
37. Yoshioka H., Mori Y., Tsukikawa S., Kubota S., Polym. Adv. Tech., 9, 155-158 (1998).
38. Shimizu S., Yamazaki M., Kubota S., Ozasa T., Moriya H., Kobayashi K., Mikami M., Mori Y., Artif. Organs, 20, 1232-1237 (1996).